Evidence for a role of vitamin D insufficiency in determining risk in Multiple Sclerosis (MS) is supported by studies in both pediatric- and adult-onset patients. The potential role of vitamin D in modulating MS disease activity is an area of active clinical trials research, and the possibility of primary disease prevention with vitamin D supplementation in early life is an emerging concept. With Sir Austin Bradford Hill's criteria as a framework, the present review assesses the evidence for a causal relationship between vitamin D insufficiency and the pathobiology of MS, and discusses rationale for future clinical trials with vitamin D. 2010 Elsevier B.V.
CITATION STYLE
H.E.C., H., & B., B. (2011). Assessment of evidence for a protective role of vitamin D in multiple sclerosis. Biochimica et Biophysica Acta - Molecular Basis of Disease. H.E.C. Hanwell, Mount Sinai Hospital, Department of Pathology and Laboratory Medicine, 600 University Ave., Toronto, ON, M5G 1X5, Canada. E-mail: heather.hanwell@gmail.com: Elsevier (P.O. Box 211, Amsterdam 1000 AE, Netherlands). Retrieved from http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=2010687968
Mendeley helps you to discover research relevant for your work.